➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Merck
Express Scripts
Moodys

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Obatoclax


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Obatoclax?

Obatoclax is an investigational drug.

There have been 19 clinical trials for Obatoclax. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Lymphoma, Lung Neoplasms, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Gemin X, National Cancer Institute (NCI), and Cephalon.

There are twenty-two US patents protecting this investigational drug and one hundred and seventeen international patents.

Recent Clinical Trials for Obatoclax
TitleSponsorPhase
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung CancerCephalonPhase 3
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 1/Phase 2
Obatoclax for Systemic MastocytosisGemin XPhase 2

See all Obatoclax clinical trials

Clinical Trial Summary for Obatoclax

Top disease conditions for Obatoclax
Top clinical trial sponsors for Obatoclax

See all Obatoclax clinical trials

US Patents for Obatoclax

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Obatoclax   Start Trial Mcl-1 antagonists The Regents of the University of California (Oakland, CA) The Royal Institute for the Advancement of Learning/McGill University (Montreal, CA)   Start Trial
Obatoclax   Start Trial Benzothiophene-based selective estrogen receptor downregulators The Board of Trustees of the University of Illinois (Urbana, IL)   Start Trial
Obatoclax   Start Trial Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same Infinity Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Obatoclax

Drugname Country Document Number Estimated Expiration Related US Patent
Obatoclax World Intellectual Property Organization (WIPO) 2015134539 2034-03-03   Start Trial
Obatoclax Australia 2016366680 2035-12-09   Start Trial
Obatoclax Brazil 112018011607 2035-12-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
AstraZeneca
Express Scripts
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.